Clinical Trial Update: Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia [Phase 3]

View source ↗

Summary

An ongoing long-term extension (Phase 3) study is evaluating Vosoritide in children with hypochondroplasia to assess long-term safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypochondroplasia

Drugs mentioned

• Vosoritide (vosoritide)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Hypochondroplasia | Phase 3 | Status: ENROLLING_BY_INVITATION